tirzepatide triple agonist Retatrutide vs Tirzepatide: Key Differences Explained – C2 Peptides Schematic illustration of monoagonists, dual
Description
Retatrutide is currently in Phase 3 clinical trials, with study completion expected in 2025
If you missed less than 4 days inject immediately
The Rationale for Dual Targeting The concept of dual GIP/GLP-1 receptor agonism emerged from observations that patients with type 2 diabetes often exhibit reduced GIP sensitivity, while GLP-1 responses may remain relatively preserved
Treatment decisions and prescribing practices are made based on the independent medical judgment of the provider's care team
Most side effects are mild, like nausea, tiredness, or diarrhoea, and improve as your body adjusts
